Novel CELMoD Phase 3 Trial Eligibility Tool
Answer a few multiple-choice questions to find a trial for your patient.
Results for eligible patients will provide links to more information.
BMS and parties it works with may store and use your responses; however, these responses are not used or matched with any personally identifiable data to identify patients.
Information you provide is governed by the BMS privacy policy.
Duration: ~3 minutes
RESULTS
Based on your responses, the following novel CELMoD trials may be right for your patient
RESULTS
Based on your responses, your patient may not be eligible for a novel CELMoD agent trial
Review Inclusion Criteria for Novel CELMoD Clinical Trials
Iberdomide phase 3 studies
now recruiting
- Iber-Dd vs DVd
- Patients with RRMM and 1-2 priors (not including anti-CD38 mAbs)
Mezigdomide phase 3 studies
now recruiting
- Mezi-Vd vs Pom-Vd
- Patients with RRMM and 1-3 priors with lenalidomide exposure
now recruiting
- Mezi-Kd vs Kd
- Patients with RRMM and ≥1 priors with lenalidomide and anti-CD38 mAb exposure
Explore other BMS-sponsored MM trials
Learn MoreEnroll a patient or find out how to register your clinic as a trial site
Email
First line of the email MUST contain the NCT # and Site #
Call 855-907-3286
Available 24/7